Acadia is bad news in my opinion for their long term holders....

Acadia is bad news in my opinion for their long term holders. I’ve owned their stock for more than 10 years. What have they done? Diluted by approximately 60% during that time and taking recent appreciation into account went up less than $5.00 during that span. They also changed their MO and began targeting rare diseases in light of their two misses on goal of expanding the Pimvanserin franchise. However, no one was better to bring Trofinetide to market. They - Acadia - needed that to win and did everything in their power to do so. Their performance with Trofinetide is an unqualified success. However in my opinion Acadia lacks the financial resources to be the best partner or acquirer of Neuren. We want one of the deepest pockets and a small fry like Acadia will not be our best option in my humble opinion. I recommend that management say no to Acadia partnering. There are superior options.